Page not found

Search results

  1. Diabetes drug study explores cardiovascular risks for patients with kidney disease

    ... of major adverse cardiovascular events when compared to a class of common diabetes drugs called sulfonylureas. The lower risk ...

    sommers - 09/27/2019 - 10:08am

  2. Vanderbilt Professor Anita Mahadevan-Jansen and her group named a Finalist for 2019 R&D 100 Awards

    ... in partnership with med device company Ai Biomed, has been selected as a Finalist for the 2019 R&D 100 Awards. The award honors 100 top innovations of the prior year, as selected by a panel of expert judges, and is in its 57th year of recognizing ...

    sommers - 10/25/2019 - 8:41am

  3. Vanderbilt Ranks 36th on the NAI's Top 100 List for U.S. Patents

    ... University ranked 36th. Published annually since 2013, the report ranks the top 100 universities named as first assignee on ...

    sommers - 06/10/2020 - 12:03pm

  4. Study tracks incidence, timing of immunotherapy-related deaths

    ... but sometimes fatal reactions to the most widely prescribed class of immunotherapies. Their research, which appeared Sept. 13 in  ...

    sommers - 02/21/2019 - 9:51am

  5. Medical device entrepreneurship opportunity for VU grad students

    ... interactive and hands-on. It is expected that half the class periods will involve lectures and the other half will involve students ...

    steelmk - 02/21/2019 - 9:51am

  6. Immunotherapies linked to specific heart complications

    ... fatal cardiac side effects from the most widely prescribed class of immunotherapies. The researchers used VigiBase, a global database of ...

    sommers - 02/21/2019 - 9:51am

  7. Ancora announces major funding awards to support Vanderbilt drug discovery research

    ... inaugural proposal review process and announced two projects selected for funding: A two-year project led by  Craig Lindsley , ... and treatment of opioid use disorders. The two selected projects will be the first to receive Ancora funding since Deerfield ...

    sommers - 02/21/2019 - 9:51am

  8. VUMC chikungunya antibody set to enter clinical trial

    ... “Our mission is to create a fundamentally new class of medicines with mRNA therapeutics that can help patients with a wide ...

    sommers - 02/27/2019 - 2:41pm

  9. EC - PreFlight Pitch Day

    ... On the evening of September 8th, entrepreneurs from the class will pitch their business concepts to a panel of judges and a live ...

    utleytj - 09/06/2016 - 4:19pm

  10. Deerfield Management and Vanderbilt University announce the launch of Ancora Innovation

    ... state-of-the-art drug development. Ancora will fund projects selected by Vanderbilt, with the aim of changing the current paradigm of drug ... The development of projects by Ancora will be selected by the Vanderbilt Selection Committee and managed through a ...

    steelmk - 04/09/2018 - 2:39pm